Израел - Хебрејски - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 1000 iu - coagulation factor viii

Израел - Хебрејски - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 2000 iu - coagulation factor viii

Израел - Хебрејски - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 250 iu - coagulation factor viii

Израел - Хебрејски - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - אבקה וממס להכנת תמיסה להזרקה - recombinant human coagulation factor viii 500 iu - coagulation factor viii

Израел - Хебрејски - Ministry of Health

j-c health care ltd - domperidone - טבליה - domperidone 10 mg - domperidone - domperidone - dyspeptic complaints associated with slow gastric evacuation or esophageal reflux such as epigastric sense of fullness, feeling of abdominal distention, upper abdominal pain, eructation, flatulence, nausea and vomiting, heartburn, with or without regurgitation of gastric contents into the mouth. nausea, vomiting and hiccups of various origin such as functional, organic, infectious, dietetic, following radiotherapy or as a result of drug therapy, in particular when induced by dopamine agonists like in parkinson's disease.

Израел - Хебрејски - Ministry of Health

sanofi israel ltd - clopidogrel as hydrogen sulfate - טבליות מצופות פילם - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Израел - Хебрејски - Ministry of Health

sanofi - aventis israel ltd - clopidogrel as hydrogen sulfate 300 mg - film coated tablets - clopidogrel - prevention of atherotrobmotic eventsclopidogrel is indicated in :• adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• adult patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapyprevention of atherotrobmotic and thromboembolic events in atrial fibrillation: in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with vitamin k antagonists (vka) anti-thrombin or anti factor xa, and who have a low bleeding risk, clopid

Израел - Хебрејски - Ministry of Health

neopharm ltd - ranolazine 1000 mg - tablets extended release - ranolazine - ranexa is indicated for the treatment of chronic angina. ranexa is also indicated as add-on therapy for the symptomati treatment of patients with chronic angina who are inadequately controlled or intolerant to other first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ace inhibitors, and angiotensin receptor blockers.

Израел - Хебрејски - Ministry of Health

neopharm ltd - ranolazine 1000 mg - tablets extended release - ranolazine - ranexa is indicated for the treatment of chronic angina. ranexa is also indicated as add-on therapy for the symptomati treatment of patients with chronic angina who are inadequately controlled or intolerant to other first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ace inhibitors, and angiotensin receptor blockers.

Израел - Хебрејски - Ministry of Health

neopharm ltd - ranolazine 500 mg - tablets extended release - ranolazine - ranexa is indicated for the treatment of chronic angina. ranexa is also indicated as add-on therapy for the symptomati treatment of patients with chronic angina who are inadequately controlled or intolerant to other first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ace inhibitors, and angiotensin receptor blockers.